DaxibotulinumtoxinA
- Generic Name
- DaxibotulinumtoxinA
- Brand Names
- Botox, Botox Cosmetic, Daxxify, Dysport, Xeomin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 93384-43-1
- Unique Ingredient Identifier
- E211KPY694
- Background
DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. It is a botulinum toxin without accessory proteins purified from the bacterium Clostridium botulinum type A, the gram-positive anaerobic bacterium primarily present in soil. C. botulinum is known to produce toxins that can cause botulism in humans.
DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines. On August 14, 2023, the drug was also approved for the treatment of cervical dystonia. DAXI or DAXXIFY, a product of daxibotulinumtoxinA, incorporates RTP004, a proprietary synthetic stabilizing peptide for enhanced product stability.
- Indication
DaxibotulinumtoxinA is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. It is also used for the treatment of cervical dystonia in adult patients.
- Associated Conditions
- Cervical Dystonia, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL)
- Associated Therapies
- -
Female Sexual Dysfunction Assessment and Managment of Vaginismus
- Conditions
- Female Sexual Dysfunction
- Interventions
- Drug: BotoxDevice: Radiofrequency
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 40
- Registration Number
- NCT06755099
- Locations
- 🇪🇬
women's health hospital of Assiut University, Assiut, Egypt
A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT06218251
- Locations
- 🇺🇸
Skin Wellness Dermatology - Homewood /ID# 248469, Birmingham, Alabama, United States
🇺🇸The Research Center at The Maas Clinic /ID# 256633, San Francisco, California, United States
🇺🇸Pacific Clinical Innovations /ID# 248467, Vista, California, United States
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
- Conditions
- Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
- Interventions
- Drug: BOTOXDrug: Placebo for BOTOX
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 83
- Registration Number
- NCT05141006
- Locations
- 🇺🇸
Alliance for Multispecialty Research (AMR) - Mobile /ID# 241002, Mobile, Alabama, United States
🇺🇸Urology Centers of Alabama /ID# 243600, Homewood, Alabama, United States
🇺🇸Sun Kim Urology /ID# 257566, Buena Park, California, United States
Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis
- Conditions
- Raynaud Phenomenon Secondary to Systemic Sclerosis
- Interventions
- Drug: Placebo groupDrug: BOTOX® solution
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 91
- Registration Number
- NCT03717961
- Locations
- 🇫🇷
Hôpital Tenon, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.